Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
27 hedge funds and large institutions have $11.3M invested in Regulus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 7 closing their positions.
318% more capital invested
Capital invested by funds: $2.71M → $11.3M (+$8.62M)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
1.94% more ownership
Funds ownership: 2.47% → 4.41% (+1.9%)
4% less funds holding
Funds holding: 28 → 27 (-1)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$2.13M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.31M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.28M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$1.13M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$68K |
| 2 |
Jane Street
New York
|
-$35.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.7K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$11.6K |
RGLS Hedge Fund Activity: Q2 2019 in Review
27 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2019, worth a combined $11.3M — up 318% from $2.71M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RGLS positions and 7 closed out — a net gain of 1 holder — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Sarissa Capital Management, opening a new position worth an estimated $2.13M. The largest seller was Virtu Financial, exiting entirely with an estimated $68K sold.
- 27 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2019, down from 28 in Q1 2019.
- Funds reported $11.3M of Regulus Therapeutics stock for Q2 2019, up 318% quarter-over-quarter.
- 8 funds opened new Regulus Therapeutics positions in Q2 2019 and 7 closed out, a net change of +1 holder.
- The largest Regulus Therapeutics buyer in Q2 2019 was Sarissa Capital Management, an estimated $2.13M added.
- The largest Regulus Therapeutics seller in Q2 2019 was Virtu Financial, an estimated $68K sold.
Based on aggregated 13F filings for Q2 2019.